Quarterly report · Q2
9987.TEDINET S100PLBR
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.14T | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥2.24T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.10T | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥14.9bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥7.1bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥16.7bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.8bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥16.5bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥13.4bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥10.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥10.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥9.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥1.19T | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥1.14T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.16T | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥764.4bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥723.7bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥429.1bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥418.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥422.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥132.9bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥141.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥155.8bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥159.0bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥28.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥9.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥37.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥123.36 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.86 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.19 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥103.75 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥108.92 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.9% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥107.1bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥19.9bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥87.2bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥930m |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥43.2bn |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥43.2bn |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5m |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥644m |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.09T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.07T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥25.1bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥12.1bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥22.7bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥17.2bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.27T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.14T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥129.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥14.7bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥85.3bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥19.4bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥65.9bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥44.0bn |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥44.0bn |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥13m |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.06T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.03T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥25.8bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥21.9bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥15.9bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥1.21T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥1.10T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥107.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥7.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 501
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments into time deposits inv cf | CurrentYTDDuration | -165000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 175000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 265000000 | JPY |
| Purchase of short term investment securities inv cf | Prior1YTDDuration | -26501000000 | JPY |
| Purchase of short term investment securities inv cf | CurrentYTDDuration | -42502000000 | JPY |
| Proceeds from sales and redemption of securities inv cf | Prior1YTDDuration | 17600000000 | JPY |
| Proceeds from sales and redemption of securities inv cf | CurrentYTDDuration | 17100000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -6192000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -8932000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YTDDuration | 18000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYTDDuration | 58000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -2576000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -1151000000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -7673000000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -2046000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | Prior1YTDDuration | 9771000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | CurrentYTDDuration | 67000000 | JPY |
| Other net inv cf | Prior1YTDDuration | -1472000000 | JPY |
| Other net inv cf | CurrentYTDDuration | 41000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -17012000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -37264000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | -10000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | － | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -214000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -191000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -4428000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -2000000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | Prior1YTDDuration | -16000000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | CurrentYTDDuration | -50000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -3212000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -3164000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -7881000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -3409000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 17000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | -42000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -9840000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -12435000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 168818000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 168215000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 158978000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 155780000000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 28435000000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 26649000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 5417000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 6475000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 552000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 439000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 1031355000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 5995000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 44024000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |